Farmakoterapiya infektsii, vyzvannoy Clostridium difficile


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The frequency and severity of community-acquired cases of Clostridium difficile infections (CDI) are increasing around the world and account for 20 to 41 % in the structure of morbidity. The article highlights the list of main preparations for the treatment of CDI for the last 30 years; and currently available data on the effectiveness of each drug are considered. A new drug, the first representative of a 18-membered macrocyclic antibiotics, fidaxomicin, is described. Results of meta-analyzes confirming higher efficiency of fidaxomicin compared with vancomycin are presented.

Full Text

Restricted Access

About the authors

E. A Ushkalova

Email: eushk@yandex.ru

References

  1. Khanna S., Pardi D.S. Clostridium Difficile Infection: Management Strategies for a Difficult Disease.Therap Adv Gastroenterol. 2014; 7(2): 72-86.
  2. Khanna S., Pardi D.S. Clostridium difficile infection: new insights into management. Mayo Clin Proc. 2012; 87(11): 1106-17.
  3. Mullane K. Fidaxomicin in Clostridium difficile Infection: Latest Evidence and Clinical Guidance. Ther Adv Chronic Dis. 2014; 5(2): 69-84.
  4. Miller B., Chen L., Sexton D. Anderson D. Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile infection and of healthcare-associated infection due to methicillin resistant Staphylococcus aureus in community hospitals. Infect Control Hosp. Epidemiol. 2011; 32: 387-90.
  5. Lessa F., Gould C., McDonald L. Current status of Clostridium difficile infection epidemiology. Clin. Infect. Dis. 2012; 55(Suppl. 2): S65-S70.
  6. Khanna S., Pardi D., Aronson S., et al. The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am. J. Gastroenterol. 2012; 107: 89-95.
  7. Fellmeth G., Yarlagadda S., Iyer S. Epidemiology of community-onset Clostridium difficile infection in a community in the South of England. J. Infect. Public Health. 2010; 3: 118-23.
  8. Khanna S., Baddour L., Huskins W., et al. The epidemiology of Clostridium difficile infection in children: a population-based study. Clin Infect Dis. 2013; 56: 1401-406.
  9. Kim J., Smathers S., Prasad P., et al. Epidemiological features of Clostridium difficile-associated disease among inpatients at children's hospitals in the United States, 20012006. Pediatrics. 2008; 122: 1266-70.
  10. McDonald L., Killgore G., Thompson A., et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N. Engl. J. Med. 2005; 353: 2433-41.
  11. Freeman J., Bauer M., Baines S., et al. The changing epidemiology of Clostridium difficile infections. Clin. Microbiol. Rev. 2010; 23: 529-49.
  12. Barbut F., Mastrantonio P., Delmee M., Brazier J., Kuijper E., Poxton I., et al. Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterization of the isolates. Clin. Microbiol. Infect. 2007; 13: 1048-57.
  13. Pepin J., Valiquette, M.E., Alary P., et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ. 2004; 171(5): 466-72.
  14. Khanna S., Pardi D., Aronson S., et al. Outcomes in community-acquired Clostridium difficile infection. Aliment Pharmacol. Ther. 2012; 35: 613-18.
  15. Clements A.C., Magalhaes R.J., Tatem A.J., Paterson D.L., Riley T.V. Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread. Lancet. Incect Dis. 2010; 10: 395-404.
  16. Slimings C., Riley T.V. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J. Antimicrob. Chemother. 2014; 69(4): 881-91.
  17. Centers for Disease Control and PreventionSevere Clostridium difficile-associated disease in populations previously at low risk - four states, 2005. MMWR Morb Mortal Wkly Rep. 2005; 54: 1201-205.
  18. Taori S.K., Wroe A., Hardie A., et al. A prospective study of community-associated Clostridium difficile infections: The role of antibiotics and co-infections. J. Infect. 2014 Apr 26. [Epub ahead of print]
  19. Centers for Disease Control and Prevention Vital signs: preventing Clostridium difficile infections. MMWR Surveill Summ. 2012; 61: 157-62.
  20. Chitnis A., Holzbauer S., Belflower R., et al. Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011. JAMA Intern Med. 2013; 173: 1359-67.
  21. Galdys A.L., Curry S.R., Harrison L.H. Asymptomatic Clostridium difficile colonization as a reservoir for Clostridium difficile infection. Expert Rev. Anti Infect. Ther. 2014; 22: 1-14. медицинской практике медиана стоимости лечения 1 пациента фидаксомицином составляет 19 483 долл. [60]. Таким образом, несмотря на достоинства фидаксомицина, его место в терапии CDI с учетом затратной эффективности еще предстоит определить в последующих исследованиях [61].
  22. Hensgens M., Keessen E., Squire M., et al. Clostridium difficile infection in the community: a zoonotic disease? Clin. Microbiol. Infect. 2012; 18: 635-45.
  23. Bouttier S., Barc M., Felix B., et al. Clostridium difficile in ground meat, France. Emerg. Infect. Dis. 2010; 16: 733-35.
  24. Metcalf D., Costa M., Dew W., Weese J. Clostridium difficile in vegetables, Canada. Lett. Appl. Microbiol. 2010; 51: 600-02.
  25. Jhung M., Thompson A., Killgore G., et al. Toxinotype V Clostridium difficile in humans and food animals. Emerg. Infect. Dis. 2008; 14: 1039-45.
  26. Weese J., Reid-Smith R., Avery B., Rousseau J. Detection and characterization of Clostridium difficile in retail chicken. Lett Appl. Microbiol. 2010; 50: 362-65.
  27. Surawicz C., Brandt L., Binion D., et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am. J. Gastroenterol. 2013; 108: 478-98.
  28. Otten A., Reid-Smith R., Fazil A., Weese, J. Disease transmission model for community associated Clostridium difficile infection. Epidemiol. Infect. 2010; 138: 907-14.
  29. Garey K.W., Sethi S., Yadav Y., DuPont H.L. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J. Hosp. Infect. 2008; 70: 298-304.
  30. Kim J., Seo M.R., Kang J.O., et al. Clinical Characteristics Of Relaspes And Reinfections In Clostridium Difficile Infection. Clin. Microbiol. Infect. 2014. Jun 4. [Epub ahead of print]
  31. Louie T.J., Miller M.A., Mullane K.M., et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N. Engl. J. Med. 2011; 364: 422-31.
  32. Cornely O.A., Crook D.W., Esposito R., et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet. Infect Dis. 2012; 12: 281-89.
  33. Abou Chakra C.N., Pepin J., Sirard S., Valiquette L. Risk Factors for Recurrence, Complications and Mortality in Clostridium difficile Infection: A Systematic Review. PLoS One. 2014; 9(6): e98400.
  34. Johnson S., Louie T.J., Gerding D.N., et al. Vancomycin, Metronidazole, or Tolevamer for Clostridium difficile Infection: Results From Two Multinational, Randomized, Controlled Trials. Rev Med Suisse. 2014; 10(427): 913-16, 918-19.
  35. Zar F., Bakkanagari S., Moorthi K. and Davis M. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile associated diarrhea, stratified by disease severity. Clin. Infect. Dis. 2007; 45: 302-07.
  36. Al-Nassir W., Sethi A., Li Y., et al. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease. Antimicrob Agents Chem. 2008; 52: 2403-406.
  37. Cohen S., Gerding D., Johnson S., et al. Clinical practice guidelines for Clostridium difficile infection in Adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010; 31: 431-55.
  38. Venugopal A.A., Johnson S. Current state of Clostridium difficile treatment options. Clin. Infect. Dis. 2012; 55(Suppl 2): S71-6.
  39. Abougergi M., Kwon J. Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review. Dig Dis Sci. 2011; 56: 19-26.
  40. Dantal J. Intravenous immunoglobulins: in-depth review of excipients and acute kidney injury risk. Am. J. Nephrol. 2013; 38(4): 275-84.
  41. Floch M.H., Walker W.A., Madsen K., et al. Recommendations for probiotic use- 2011 update. J. Clin. Gastroenterol. 2011; 45: 168-71.
  42. Fitzpatrick L.R. Probiotics for the treatment of Clostridium difficile associated disease. World J Gastrointest Pathophysiol. 2013; 4(3): 47-52.
  43. O'Horo J.C., Jindai K., Kunzer B., Safdar N. Treatment of recurrent Clostridium difficile infection: a systematic review. Infection. 2014; 42(1): 43-59.
  44. Vindigni S.M.1, Broussard E.K., Surawicz C.M. Alteration of the intestinal microbiome: fecal microbiota transplant and probiotics for Clostridium difficile and beyond. Expert Rev. Gastroenterol. Hepatol. 2013; 7(7): 615-28.
  45. Surawicz C.M., Alexander J. Treatment of refractory and recurrent Clostridium difficile infection. Nat Rev Gastroenterol. Hepatol. 2011; 8(6): 330-39.
  46. Tissot F., Maillard M.H. Clostridium difficile infections: update on new European recommandations. Am. J. Gastroenterol advance online publication, 2014.
  47. Artsimovitch I., Seddon J., Sears P. Fidaxomicin is an inhibitor of the initiation of bacterial RNA synthesis. Clin. Infect. Dis. 2012; 55(Suppl. 2): S127-31.
  48. Biedenbach D., Ross J., Putnam S., Jones R. In vitro activity of fidaxomicin (OPT-80) tested against contemporary clinical isolates of Staphylococcus spp. and Enterococcus spp. Antimicrob Agents Chem. 2010; 54: 2273-75.
  49. Babakhani F., Bouillant L., Gomez A., et al. Fidaxomicin inhibits spore production in Clostridium difficile. Clin. Inf. Dis. 2012; 55(Suppl. 2): S162-69.
  50. Babakhani F., Bouillaut L., Sears P., et al. Fidaxomicin inhibits toxin production in Clostridium difficile. J. Antimicrob. Chemother. 2013; 68(3): 515-22.
  51. Louie T., Cannon K., Byrne B., et al. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin re-expression and recurrence of CDI. Clin. Infect. Dis. 2012; 55(Suppl. 2): S132-42.
  52. Hecht D., Galang M., Sambol S., et al. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Ag Chem. 2010; 51: 2716-19.
  53. Babakhani F., Gomez A., Robert N., Sears P. Postantibiotic effect of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile. Antimicrob Agents Chem. 2011; 55: 4427-29.
  54. Nerandzic M., Mullane K., Miller M., et al. Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida spp. in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection. Clin. Infect. Dis. 2012; 55(Suppl. 2): S121-26.
  55. Tannock G., Munro K., Taylor C., et al. New macrocycle antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiol. 2010; 156: 3354-59.
  56. Mullane K., Miller M., Weiss K., et al. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin. Infect. Dis. 2011; 53: 440-47.
  57. Crook D., Walker A., Kean Y., et al. Fidaxomicin versus vancomycin for Clostridium difficile infection: metaanalysis of pivotal randomized controlled trials. Clin. Infect. Dis. 2012; 55(Suppl. 2): S93-S103.
  58. Cornely O.A., Miller M.A., Fantin B., et al. Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin. J. Clin. Oncol. 2013; 31(19): 2493-99.
  59. Cornely O.A., Miller M.A., Louie T.J., et al. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin. Infect. Dis. 2012; 55(Suppl 2): S154-61.
  60. Vargo C.A., Bauer K.A., Mangino J.E., et al. An Antimicrobial Stewardship Program's Real-World Experience with Fidaxomicin for Treatment of Clostridium difficile Infection: A Case Series. Pharmacotherapy. 2014 Jun 5. [Epub ahead of print].
  61. Scott L.J. Fidaxomicin: a review of its use in patients with Clostridium difficile infection. Drugs. 2013; 73(15): 1733-47.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies